Welcome to our dedicated page for Kymera Therapeutics news (Ticker: KYMR), a resource for investors and traders seeking the latest updates and insights on Kymera Therapeutics stock.
Kymera Therapeutics develops targeted protein degradation medicines for immunological diseases as a clinical-stage biopharmaceutical company. News about KYMR commonly centers on oral small molecule degrader programs, including KT-621, a STAT6 degrader for Type 2 inflammatory diseases such as atopic dermatitis and asthma, and KT-579, an IRF5 degrader tied to inflammatory bowel disease biology.
Company updates also cover preclinical and clinical data presentations, FDA regulatory designations, collaboration activity involving degrader candidates such as KT-200, and periodic operating and financial results. Additional announcements include investor conference participation and shareholder voting matters.
Kymera Therapeutics, a biopharmaceutical company focused on targeted protein degradation, announced that CEO Nello Mainolfi will present at the Morgan Stanley 18th Annual Global Healthcare Conference on September 16, 2020, at 5:00 p.m. ET. The presentation can be accessed via a live webcast on the company's website, with an archived version available for 90 days. Kymera's focus includes developing therapeutics that target difficult disease-causing proteins, specifically through its Pegasus platform, addressing immune-inflammatory diseases and tumors.
Kymera Therapeutics (NASDAQ: KYMR) announced the appointment of Pamela Esposito, PhD, and Jeff Albers, JD, to its Board of Directors. Both bring extensive biopharmaceutical experience, enhancing Kymera's leadership during a pivotal growth phase. Dr. Esposito has been instrumental in raising over $400M for Replimune's oncolytic therapies, while Albers led Blueprint Medicines through a successful IPO. Their expertise is expected to advance Kymera's strategic direction and innovative treatment options for cancer and autoimmune diseases.
Kymera Therapeutics (NASDAQ: KYMR) announced the closing of its upsized initial public offering, selling 9,987,520 common shares at $20.00 per share, yielding approximately $199.8 million in gross proceeds. This includes 1,302,720 shares purchased by underwriters' option. Additionally, Kymera completed a private placement of 676,354 shares to Vertex Pharmaceuticals, raising $13.5 million. Registration statements for these offerings were effective as of August 20, 2020. All shares were sold by Kymera, aimed at advancing targeted protein degradation therapeutics.